SMOC2 and neoplasm: As previously described, tumours from STmΔaroA treated mice had reduced expression of tumour stem cell markers Lgr5 and Smoc2, with a strong trend in Vim, a mesenchymal marker (Mackie et al, 2021), which is a desirable outcome for tumour control (Fig. 8J).